Wall Street analysts expect Cellectis SA (NASDAQ:CLLS) to report $10.10 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Cellectis’ earnings, with estimates ranging from $9.00 million to $11.31 million. Cellectis posted sales of $13.02 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.4%. The firm is scheduled to report its next quarterly earnings results on Monday, March 5th.
On average, analysts expect that Cellectis will report full-year sales of $10.10 million for the current fiscal year, with estimates ranging from $34.00 million to $39.85 million. For the next year, analysts expect that the company will report sales of $40.21 million per share, with estimates ranging from $33.00 million to $45.22 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Cellectis.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%.
A number of hedge funds have recently modified their holdings of CLLS. Wells Fargo & Company MN lifted its holdings in Cellectis by 132.1% in the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares in the last quarter. Balyasny Asset Management LLC acquired a new position in Cellectis in the 2nd quarter worth $719,000. Advisors Asset Management Inc. lifted its holdings in Cellectis by 1,501.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock worth $643,000 after buying an additional 21,181 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in Cellectis by 71.1% in the 3rd quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after buying an additional 144,972 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Cellectis in the 3rd quarter worth $517,000. Hedge funds and other institutional investors own 16.42% of the company’s stock.
Cellectis (NASDAQ CLLS) opened at $29.74 on Wednesday. Cellectis has a 1-year low of $19.76 and a 1-year high of $35.07.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/07/brokerages-expect-cellectis-sa-clls-will-announce-quarterly-sales-of-10-10-million.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.